NASDAQ · Biotechnology · USD
Oramed Pharmaceuticals Inc. (ORMP) Stock Analysis
Oramed Pharmaceuticals Inc. (ORMP) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.
Last Updated: October 21, 2026
Price History
No price data available
Hover for the daily close. The dotted line marks the period open.
ORMP Key Statistics
As of Oct 21, 2026Trading
- Open
- $4.16
- Previous Close
- $4.15
- Day's Range
- 4.06–4.17
- 52-Week Range
- 2.09–5.47
- Volume
- 84.30K
- BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
- 1.28
Valuation
- Market Cap
- $172.21M
- P/E Ratio
- 1.00
- EPS (ttm)Profit attributable to each share over the last twelve months.
- 4.13
Financials (FY)
- Revenue (FY)
- $2.00M
- Net Income (FY)
- $64.05M
- Shares Outstanding
- 41.60M
- 1-Year Return
- +89.78%
Dividend and dates
- Dividend
- $0.25+6.02%
- Ex-Dividend Date
- January 16, 2026
- Earnings Date
- November 12, 2026estimated
- Avg Volume
- 187.43K
Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.
Key facts
As of October 21, 2026, ORMP closed at $4.14, +89.78% over 1 year.
Oramed Pharmaceuticals Inc. (ORMP) has a market capitalization of $172.21M.
In fiscal 2025, ORMP reported revenue of $2.00M.
ORMP Stock Return by Calendar Year
Oramed Pharmaceuticals Inc. (ORMP) 10-year return: what $10,000 became
- 1 year
- $10,000 $18,978
- +89.78%
- 5 years
- $10,000 $1,984
- −80.16%
- 10 years
- $10,000 $6,427
- −35.73%
If you had invested $10,000 in Oramed Pharmaceuticals Inc. (ORMP) 10 years ago, at the close on October 21, 2016, it would have been worth $6,427 at the close on October 21, 2026: −35.73% in total, −4.32% a year, with dividends reinvested. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.
Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.
| Year | Return |
|---|---|
| 2026 (partial year) | +55.82% |
| 2025 | +17.77% |
| 2024 | +4.76% |
| 2023 | −80.80% |
| 2022 | −15.76% |
| 2021 | +236.80% |
| 2020 | −17.67% |
| 2019 | +71.67% |
| 2018 | −66.67% |
| 2017 | +47.06% |
| 2016 (partial year) | −22.92% |
As of October 21, 2026.
ORMP Revenue and Earnings by Fiscal Year
FY ends December| Fiscal year | Revenue | Net income | Net margin |
|---|---|---|---|
| 2025 | $2.00M | $64.05M | 3,202.5% |
| 2024 | $0.00 | −$19.06M | — |
| 2023 | $1.34M | $5.53M | 412.3% |
| 2022 | $2.70M | −$36.56M | −1,352.6% |
| Fiscal year | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2025 | $2.00M | $13.00K | −$15.09M | $64.05M | 3,202.5% |
| 2024 | $0.00 | $0.00 | −$12.78M | −$19.06M | — |
| 2023 | $1.34M | — | −$15.77M | $5.53M | 412.3% |
| 2022 | $2.70M | — | −$40.60M | −$36.56M | −1,352.6% |
Annual figures as reported, in the company's reporting currency. As of December 31, 2025.
ORMP Valuation vs Biotechnology Median
Median of 608 stocks| Metric | ORMP | Biotechnology median | vs median |
|---|---|---|---|
| P/E | 1.00 | 16.60 | 0.1x the median |
Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.
Recent News
News provided by third-party sources. Not financial advice.
Analysis
Data-derivedEvery figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.
Related Biotechnology Stocks
Vertex Pharmaceuticals Incorporated
$132.95B
MRNAModerna, Inc.
$98.14B
REGNRegeneron Pharmaceuticals, Inc.
$82.95B
ARGXargenx SE
$55.97B
ONCBeOne Medicines AG
$43.97B
RVMDRevolution Medicines, Inc.
$41.64B
Popular Healthcare Stocks
Eli Lilly and Company
$1.13T
JNJJohnson & Johnson
$621.22B
ABBVAbbVie Inc.
$503.27B
UNHUnitedHealth Group Incorporated
$374.30B
MRKMerck & Co., Inc.
$369.78B